PPT: Depression Drugs Market To Witness Huge Growth during 2020-2025

Global Depression Drugs Market Research Report and Forecast 2025

Report Edition: 2020 © 2020 IMARC All Rights Reserved

Copyright © IMARC Service Pvt Ltd. All Rights Reserved

About IMARC Group

Report Description

The International Market Analysis Research and Consulting Group is a leading adviser on management strategy and market research worldwide. We partner with clients in all sectors and regions to identify their highest-value opportunities, address their most critical challenges, and transform their businesses.

IMARC’s information products include major market, scientific, economic and technological developments for business leaders in pharmaceutical, industrial, and high technology organizations. Market forecasts and industry analysis for biotechnology, advanced materials, chemicals, food and beverage, travel and tourism, nanotechnology and novel processing methods are at the top of the company’s expertise.

IMARC’s tailored approach combines unfathomable insight into the dynamics of companies and markets with close cooperation at all levels of the client organization. This ensures that our clients achieve unmatchable competitive advantage, build more proficient organizations, and secure lasting results.

Report Description and Highlights

Report Description

Global Depression Drugs Market Overview: According to the latest report by IMARC Group, titled “ Depression Drugs Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 202 0-2025 ”, the global depression drugs market size is expanding at a steady rate. Depression is a serious mental health disorder that negatively affects the way one feels, thinks and acts. It is characterized by persistent feelings of sadness and/or loss of interest. It is a severe illness that can lead to a variety of emotional and physical problems while decreasing the patient’s ability to function at work and home.

After identifying specific symptoms and medical history, depression drugs are usually prescribed to the patients to help modify their brain chemistry. The purpose of these medicines is to balance the neurotransmitters in the brain, which affect mood and emotions. Apart from being used to treat depression, these drugs are also widely used to treat other mental health conditions, including anxiety disorders, attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD).

Request for a free sample report: https://www.imarcgroup.com/depression-drugs-market/requestsample

Report Description and Highlights

Report Description

Global Depression Drugs Market Trends: The increasing awareness regarding the prevalence of depression and other mental illnesses has led a majority of the population to seek professional help, which is primarily driving the market. Hectic lifestyles, improper dietary habits and long working hours, along with social isolation and stressful work environment, have resulted in the development of stress disorders among the working population, which is another major factor boosting the sales of depression drugs. Moreover, the increasing geriatric population is another major growth-inducing factor.

The elderly population is more prone to health disorders, which may be followed by mental illnesses.

Also, elderlies are more likely to endure the sense of social isolation, especially from the immediate family members and friends, which consequently leads to depression. Furthermore, manufacturers are continually engaging in research and development (R&D) activities to introduce effective variants with minimal side-effects and prolonged results. On account of the aforementioned factors, the market is anticipated to reach to grow at a CAGR of 2.3% during 2020-2025.

Report Description and Highlights

Report Description

Global Depression Drugs Market Segmentation: Breakup by Drug Class: • • • • • • •

Atypical Antipsychotics, Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) Selective Serotonin Reuptake Inhibitors (SSRIs) Central Nervous System (CNS) Stimulants Tricyclic Antidepressants Monoamine Oxidase Inhibitors others

On the basis of the drug class, the market has been divided into Atypical Antipsychotics, SerotoninNorepinephrine Reuptake Inhibitors (SNRIs), Selective Serotonin Reuptake Inhibitors (SSRIs), Central Nervous System (CNS) Stimulants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors and others.

Report Description and Highlights

Report Description Breakup by Disorder Type: • • • •

Obsessive-compulsive Disorder Generalized Anxiety Disorder Panic Disorder Other Disorders

Based on the disorder type, major depressive disorder accounts for a majority of the total market share. Other segments include obsessive-compulsive, generalized anxiety, panic and other disorders.

Breakup by Drug Type: • •

Generic Drugs Branded Drugs

On the basis of the drug type, the market has been bifurcated into generic and branded drugs.

Report Description and Highlights

Report Description Breakup by Distribution Channel:

• Hospitals • Online • Other Pharmacies Based on the distribution channel, retail pharmacies exhibit a clear dominance in the market. Other segments include hospitals, online and other pharmacies.

Market Segmentation by Region: • • • • •

North America Europe Asia Pacific Middle East and Africa Latin America

On the geographical front, the market has been segregated into North America (the United States and Canada), Europe (Germany, France, the United Kingdom, Italy, Spain, Russia and others), Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia and others), Latin America (Brazil, Mexico and others), and Middle East and Africa.

Report Description and Highlights

Report Description Competitive Landscape:

The competitive landscape of the market has also been examined with some of the key players.

• • • • • • • • • • • •

Otsuka Pharmaceutical Co., Ltd. Pfizer Inc. Eli Lilly and Company AstraZeneca plc Novartis International AG Bristol-Myers Squibb Company GlaxoSmithKline plc Takeda Pharmaceutical Company Ltd. Allergan plc Johnson & Johnson Zhejiang NHU Co., Ltd. Sebela Pharmaceuticals Inc

Report Description and Highlights

Report Description

The competitive landscape of the market has also been analyzed with the detailed profiles of the key players operating in the market. Some of these include Otsuka Pharmaceutical Co., Ltd., Pfizer Inc., Eli Lilly and Company, AstraZeneca plc, Novartis International AG, Bristol-Myers Squibb Company, GlaxoSmithKline plc, Takeda Pharmaceutical Company Ltd., Allergan plc, Johnson & Johnson, Zhejiang NHU Co., Ltd., and Sebela Pharmaceuticals Inc. For more information, click here: https://www.imarcgroup.com/depression-drugs-market Browse Other Report by IMARC Group: Global Generic Drugs Market Report 2020-2025 Global Generic Injectables Market Report 2020-2025

A partial List of

We are the trusted business partners to the

Clients world's leading corporates, governments, and ourPartial ClientsList of institutions

A partial List of

We are the trusted business partners to the

of Clients leading corporates, governments, and ourPartial ClientsListworld's institutions

Report Description and Highlights

Report Description

Š 2020 IMARC All Rights Reserved This Publication and all it’s contents unless otherwise mentioned are copyrighted in the name of International Market Analysis Research and Consulting (IMARC). No part of this publication may be reproduced, repackaged, redistributed or resold in whole or in any part. The publication may also not be used in any form or by and means graphic electronic or mechanical, including photocopying, recording, taping or by information storage or retrieval, or by any other form, without the express consent of International Market Analysis Research and Consulting (IMARC).

Disclaimer: All contents and data of this publication, including forecasts, data analysis and opinion have been based on information and sources believed to be accurate and reliable at the time of publishing. International Market Analysis Research and Consulting makes no representation of warranty of any kind as to the accuracy or completeness of any Information provided. IMARC accepts no liability whatsoever for any loss or damage resulting from opinion, errors or inaccuracies if any found this publication.

IMARC, IMARC Group and Global Therapy Insight Series are registered trademarks of International Market Analysis Research and Consulting. All other trademarks used in this publication are registered trademarks of their respective companies.

Contact Us

FOR MORE DETAILS Visit us at :

https://www.imarcgroup.com Stay With Us:

TELEPHONE: +1-631-791-1145 E-MAIL: sales@imarcgroup.com